Else Nutrition Cuts Costs, Returns to Profit Amid Regulatory Tailwinds
Event summary
- Else Nutrition reported $6.0M revenue in 2025, down 18.5% YoY, but reduced operating expenses by 51% to $6.7M, returning to positive gross profit of $320K.
- Cost of goods sold (COGS) declined by 38%, with one-time write-offs of CAD $750K, and gross profit margin (GPM) improved in the second half of 2025.
- U.S. regulatory environment shifted with Congressional directive for FDA to establish clearer approval pathways for plant-based infant formulas under Operation Stork Speed.
- FDA announced intent to finalize updated Protein Efficiency Ratio (PER) guidance in March 2026, removing a key blocker for Else's clinical studies.
- Company aims for cash-flow breakeven between late 2026 and early 2027, with resumed shipments to Canadian retailers at higher margins.
The big picture
Else Nutrition's strategic pivot toward cost reduction and operational efficiency has positioned it for profitability amid a shifting regulatory landscape. The FDA's moves to streamline approval pathways for plant-based infant formulas represent a critical inflection point for the category, potentially expanding market opportunities for Else's innovative solutions. The company's ability to capitalize on these tailwinds will be key to its long-term success.
What we're watching
- Regulatory Tailwinds
- How FDA's updated PER guidance will accelerate Else's U.S. market entry and whether the regulatory shift sustains long-term growth.
- Operational Execution
- The pace at which Else can close inventory gaps and resume growth in major retail channels after prolonged out-of-stock periods.
- Profitability Path
- Whether Else can maintain its cost optimization efforts and achieve the targeted annual GPM of 30% and above by 2026.